53 research outputs found
A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) – European society for clinical and economic aspects of osteoporosis and osteoarthritis (ECCEO), outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people
A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice:the VEGF Consortium
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives
Faut-il suivre par IRM hypophysaire les patients porteurs de macroprolactinome dont l'hypersécrétion est contrôlée médicalement ?
Somatostatin and dopamine receptors quantitative mRNA expression in 31 pheocromocytomas and paragangliomas.
Faut-il suivre par IRM hypophysaire les patients porteurs de macroprolactinome dont l’hypersécrétion est contrôlée médicalement ?
156 PIOGLITAZONE, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONIST REDUCES INFLAMMATORY-INDUCED ALTERATION OF BONE STRUCTURE IN RAT ADJUVANT POLYARTHRITIS: EVIDENCE FOR A BONE PROTECTING EFFECT IN INFLAMMATORY CONDITIONS
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment
International audienceObjective: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. Patients and methods: We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained. Results: In total, 115 patients were included (63 men and 52 women; mean age at diagnosis: 36.3 years). Mean baseline prolactin level was 2224 ± 6839 ng/mL. No significant increase of tumor volume was observed during the follow-up. Of the 21 patients (18%) who presented asymptomatic hemorrhagic changes of the macroprolactinoma on MRI, 2 had a tumor increase (2 and 7 mm in the largest size). Both were treated by cabergoline (1 mg/week) with normal prolactin levels obtained for 6 and 24 months. For both patients, no further growth was observed on MRI during follow-up at the same dose of cabergoline. Conclusion: No significant increase of tumor size was observed in our patients with controlled prolactin levels on DA. MRI follow-up thus appears unnecessary in patients with biologically controlled macroprolactinomas
- …